ArticleBMC complementary medicine and therapies2025
Violacein: a natural antibacterial agent empowered by film-forming sprays for topical applications.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveThe rise of antibiotic-resistant microorganisms poses a significant public health threat. Exploring natural compounds with antibacterial properties offers a potential solution. Violacein, derived from Chromobacterium violaceum, has shown promise for its antibacterial and antioxidant effects. This study aims to develop and evaluate a violacein-loaded film-forming spray (FFS) to enhance patient adherence through a flexible, peelable skin film, while maintaining antibacterial efficacy.
methodsThe antibacterial and antioxidant activities of violacein crude extract were evaluated. Then a central composite design was employed to optimize the FFS formulation by varying the concentration of the film-forming agent (Eudragit® RS 100), solvent ratio (ethanol), and diethyl phthalate (plasticizer). The properties of both liquid and film forms were characterized.
resultsViolacein exhibits both antibacterial and antioxidant effects. Altering the concentration of Eudragit® RS 100 and the ethanol-to-water ratio impacts viscosity, drying time, and toughness, affecting the spray radius. Increasing diethyl phthalate concentration reduces stress (the force the film can withstand before deformation) and Young’s modulus (a measure of stiffness) but increases strain (the film’s ability to stretch before breaking). The optimized formulation consists of 17.41%w/w Eudragit® RS 100, 20%w/w diethyl phthalate (DEP), and a 4:1 (w/w) ethanol-to-water ratio, producing a flexible, durable film with a wide spray radius and viscosity ranging from 0.025 to 0.045 Pa·S. Importantly, the violacein-loaded FFS exhibits superior antibacterial activity compared to a commercial clindamycin solution.
conclusionThe developed violacein-loaded FFS successfully generated a flexible and durable film, with significant in vitro antibacterial activity. This evidence suggests its potential for further development as an effective topical formulation that may enhance patient adherence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.